Dr. Nancy Cheng Maly, MD

Dr. Maly practices at Sharp Rees-Stealy Medical Group, Inc in San Diego, California.

Dr. Maly's NPI, 1073874178, was assigned on June 5, 2012. Dr. Maly graduated from The Johns Hopkins University School of Medicine in 2012. Dr. Maly holds California license A128986.

Dr. Maly's primary practice is Sharp Rees-Stealy Medical Group, Inc, at 5651 Copley Dr, San Diego, CA 92111 in San Diego County. The practice phone is (858) 262-6666.

Dr. Maly's primary practice is Sharp Rees-Stealy Medical Group, Inc in San Diego, California. The medical group on file is Sharp Rees-Stealy Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maly practices. Vendor and product names are available with a free account.

Dermatology is Dr. Maly's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Maly is board certified in dermatology by the American Board of Dermatology. Dr. Maly is licensed in California.

Dmand AI lists acne, benign or precancerous skin growths, contact dermatitis, itchy rashes, psoriasis and skin cyst among the conditions Dr. Maly treats.

CMS data shows 330 Medicare services from Dr. Maly across 8 procedure codes in 2024, for 120 Medicare patients. Medicare paid $17,196 for them. Every service was in an office.

CMS counts 120 Medicare patients who saw Dr. Maly in 2024. The largest group is 65 to 74, with 56 patients. 69% of them have high cholesterol, and 63% have high blood pressure. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Maly's median patient age at 56, with 60% women.

In 2024, Dr. Maly wrote 276 Medicare Part D claims for 110 patients. 92% of them were for generic drugs. CMS names the drug for 200 of them, across 7 drugs with 11 or more claims each, at $52,934 in total drug cost. In 2023, CMS named 144 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Maly for performance year 2024, reported as part of a group. Dr. Maly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 47 procedures of removal of skin lesions by Dr. Maly, more than 71% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Maly.

CMS Open Payments shows 114 general payments to Dr. Maly from 25 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 92% of the total. Pfizer Inc. paid the most, $599.

Dr. Maly graduated from The Johns Hopkins University School of Medicine in 2012.